Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.

Vicente Plaza; Isam Alobid; Cesáreo Álvarez; Marina Blanco; Jorge Ferreira; Gabriel García; Antonio Gómez‐Outes; Fernando Gómez; Antonio Hidalgo Navarro; Javier Korta; Jesús Molina; F Pellegrini; Montserrat Pérez-Encinas; Manuel Praena; Santiago Quirce; José Sanz

doi:10.1016/j.arbres.2021.05.010

February 1, 2022

Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.

View at Publisher

Ask AI

Bookmark

Share

Key Points

To review the key updates, therapeutic recommendations, and controversies introduced in the Spanish Asthma Management Guidelines (GEMA version 5.1).
Consensus-based revision of clinical criteria and treatment recommendations across asthma severity classifications, ranging from intermittent to severe disease.
Integration of specialized management strategies addressing comorbidities, pediatric scoring tools, COVID-19, and health system organization.
Intermittent and mild asthma protocols expand the use of as-needed inhaled glucocorticoid/adrenergic combinations as an alternative strategy to address low adherence to daily maintenance steroids.
Severe asthma recommendations incorporate revised phenotype classifications, single-inhaler triple therapy regimens, and structured eligibility criteria for biologic therapies in uncontrolled disease.
Guideline additions establish pediatric scoring metrics, clinical care pathways for asthma units and telemedicine, and targeted guidance for COVID-19 and nasal polyposis.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical guideline review demonstrates updated management pathways in asthma patients, highlighting targeted biologic and single-inhaler combination therapies across severity stages.

Abstract

cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Plaza et al. (2022) studied this question.

synapsesocial.com/papers/6a974ae8d95974d8d37fd1c5 https://doi.org/10.1016/j.arbres.2021.05.010

View at Publisher

Ask AI

Bookmark

Share

Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading